Search Results

You are looking at 51 - 60 of 929 items for :

  • "NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines" x
  • Refine by Access: All x
Clear All
Full access

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Naresh Bellam, William Blum, Michael W. Boyer, Hetty E. Carraway, Peter F. Coccia, Steven E. Coutre, Jennifer Cultrera, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Haydar Frangoul, Olga Frankfurt, Salil Goorha, Michael M. Millenson, Susan O'Brien, Stephen H. Petersdorf, Arati V. Rao, Stephanie Terezakis, Geoffrey Uy, Meir Wetzler, Andrew D. Zelenetz, Maoko Naganuma, and Kristina M. Gregory

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Acute Lymphoblastic Leukemia (ALL) were developed as a result of meetings convened by a multidisciplinary panel of ALL experts, with the goal of providing recommendations on standard

Full access

William T. McGivney

The National Comprehensive Cancer Network (NCCN) and our 21 member institutions are dedicated to improving the care available to patients around the world. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) and the attendant

Full access

Andrew D. Zelenetz and Pamela S. Becker

granulocyte colony-stimulating factor (G-CSF) filgrastim-sndz. Filgrastim-sndz is now listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors (MGFs) and is part of many drug formularies. The oncology community

Full access

Robert W. Carlson and Eric Jonasch

NCCN Evidence Blocks to Guide Decision-Making NCCN recently introduced NCCN Evidence Blocks into a number of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to assist clinicians and patients as they grapple with treatment

Full access

Jerald P. Radich

-positive (Ph+) marrow metaphases,” as they correspond to long-term outcomes such as progression-free and overall survival (OS). The treatment options recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for chronic-phase CML

Full access

Waleed A. Hassen, Farrok A. Karsan, Farhat Abbas, Yasar Beduk, Ahmed El-Khodary, Marwan Ghosn, Jamal Khader, Raja Khauli, Danny M. Rabah, Ali Shamseddine, and Sandy Srinivas

Africa (MENA) region is not completely known. A prostate cancer committee was established to modify the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Prostate Cancer for adaptation and implementation in the MENA region. The objective

Full access

Robert W. Carlson

The uses and distribution of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) continue to increase dramatically, with more than 3 million downloads from the NCCN Web site in 2010 alone. More than 230,000 individuals in 194

Full access

and includes a variety of regimen choices. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) endorse a number of anthracycline- and non-anthracycline–based options. Data in this figure are adapted from distribution data provided by

Full access

Arti Hurria

. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Senior Adult Oncology include a comprehensive geriatric assessment that can be used to help predict the risk of toxicity from cancer treatment in older patients. Along with age

Full access

Ali Bazarbachi and Andrew D. Zelenetz

East and North Africa) region guideline committees began the process of modifying the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for several tumor types, including lymphoma. The MENA region includes Morocco, Algeria, Tunisia